You are here

CDC Awards $28.6 Million to Help States Fight Opioid Overdose Epidemic

Support will strengthen state efforts to prevent and track opioid overdoses

The Centers for Disease Control and Prevention (CDC) is awarding more than $28.6 million in additional funding to 44 states and the District of Columbia to support their responses to the opioid overdose epidemic. The funds will be used to strengthen prevention efforts and better track opioid-related overdoses.

“One piece of HHS’s five-point strategy for combating the opioid crisis is improving our understanding of the epidemic through better public health data,” said Health and Human Services Secretary Tom Price, MD. “The expansion of these CDC programs, made possible by legislation President Trump signed earlier this year, is an important piece of our commitment to helping states combat the scourge of opioid addiction and overdose.”

In July 2017, the CDC said that it was providing a separate $12 million to states to support overdose prevention activities.

Increased funding for opioids in the fiscal year (FY) 2017 Omnibus Appropriations bill is allowing CDC to support all states funded under its Overdose Prevention in States (OPIS) effort, which includes three programs that equip states with resources needed to address the epidemic. The three programs are: Prescription Drug Overdose: Prevention for States (PfS), the Data-Driven Prevention Initiative (DDPI), and Enhanced State Opioid Overdose Surveillance (ESOOS).

Under the PfS program, $19.3 million in funding will go to 27 states in program expansion supplemental awards. Under the DDPI, $4.6 million in funding will go to 12 states and Washington, D.C., in program expansion supplemental awards. Funds will be used by states to scale up prevention activities that include increasing the use of prescription drug monitoring programs and improving clinical feedback from these systems, expanding the reach of messages about the risks associated with opioids, and other practices such as conducting overdose fatality reviews to improve prevention efforts.

PfS supplemental awardees are: Arizona, California, Colorado, Connecticut, Delaware, Illinois, Indiana, Kentucky, Maryland, Massachusetts, Nebraska, Nevada, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Rhode Island, South Carolina, Tennessee, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.

DDPI supplemental awardees are: Alabama, Alaska, Arkansas, Georgia, Idaho, Kansas, Louisiana, Michigan, Minnesota, Montana, New Jersey, South Dakota, and Washington, D.C.

Under the ESOOS program, $4.7 million will go to 32 states and Washington, D.C., to better track and prevent opioid-involved nonfatal and fatal overdoses. Funds will be used by states to directly support medical examiners and coroners, including funds for comprehensive toxicology testing and for enhancing their surveillance activities. ESOOS supplemental awardees are: Alaska, California, Connecticut, Delaware, Florida, Georgia, Illinois, Indiana, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, North Carolina, Ohio, Oklahoma, Pennsylvania, Rhode Island, Tennessee, Utah, Vermont, Virginia, Washington, Washington, D.C., West Virginia, and Wisconsin.

The expanded funding is part of the Department of Health and Human Services’ five-point strategy to fight the opioid epidemic by:

  • Improving access to prevention, treatment, and recovery services, including the full range of medication-assisted treatments;
  • Targeting availability and distribution of overdose-reversing drugs;
  • Strengthening our understanding of the crisis through better public health data and reporting;
  • Providing support for cutting edge research on pain and addiction; and
  • Advancing better practices for pain management.

Source: CDC; September 5, 2017.

More Headlines

Easier-to-clean Pentax device may help limit bacterial infections
First once-daily, single-inhaler triple therapy for the disease in the U.S.
Such drugs often block the serotonin that other organs need
Proprietary delivery system deposits proven steroid deep into the nose
Patient deaths related to other combination therapies concern the agency
Detailed procedures aim to protect patients from promising treatment’s toxicities
PFS worse with bendamustine and rituximab in new study
Single-dose oral therapy treats leading gynecological infection